US Broker Ratings

Ardelyx, Inc. (ARDX) Stock Analysis: Is a 294% Upside Potential Within Reach for Investors?

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company dedicated to addressing unmet medical needs, is currently trading at $3.27 per share. With a market capitalization of $844.27 million, Ardelyx is positioned..

Immunome, Inc. (IMNM) Stock Analysis: Exploring an 82% Upside Potential Amid Biotech Advances

Immunome, Inc. (NASDAQ: IMNM), a burgeoning player in the biotechnology sector, is turning heads with its promising pipeline and a compelling potential upside of 82.29% as indicated by analyst ratings...

Embecta Corp. (EMBC) Stock Report: A Closer Look at Its 30% Downside Potential Amidst Sector Challenges

Embecta Corp. (NASDAQ: EMBC), a stalwart in the healthcare sector with a focus on medical instruments and supplies, is navigating a challenging landscape. With a market capitalization of $325.79 million,..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring the Potential in Biotech Innovation

Anavex Life Sciences Corp. (NASDAQ: AVXL) stands at the forefront of the biotechnology sector, captivating investor interest with its dedication to developing treatments for complex neurological conditions. With a market..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: A Biotech Stock with a 105% Potential Upside

Bicara Therapeutics Inc. (NASDAQ: BCAX) is a compelling player in the biotechnology sector, attracting significant attention from investors with its promising pipeline and potential for substantial upside. With a market..

HealthStream, Inc. (HSTM) Stock Analysis: Revenue Growth and Strategic Positioning in Healthcare SaaS

HealthStream, Inc. (NASDAQ: HSTM) continues to make its mark in the healthcare sector, leveraging its innovative Software-as-a-Service (SaaS) applications to offer comprehensive solutions for healthcare organizations across the United States...

Rocket Pharmaceuticals, Inc. (RCKT)

⚠️ No article content returned.

..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring the 579.89% Potential Upside

LENZ Therapeutics, Inc. (NASDAQ: LENZ) presents an intriguing opportunity within the biotechnology sector for investors willing to navigate its high-risk, high-reward landscape. Headquartered in Solana Beach, California, LENZ Therapeutics focuses..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Exploring a 67% Upside Potential in Cancer Therapy Innovations

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is making waves with its promising developments in cancer therapies. Despite recent stock price fluctuations, with the current price at $23.83,..

Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring 162% Upside Potential in Biotech Innovation

Nuvation Bio Inc. (NUVB), a clinical-stage biopharmaceutical firm based in New York, is making waves in the biotechnology sector with its promising pipeline focused on cancer treatments. With a current..

Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotech with 144% Upside Potential

For investors looking into the dynamic world of biotechnology, Praxis Precision Medicines, Inc (NASDAQ: PRAX) presents a compelling opportunity with a significant potential upside. As a clinical-stage biopharmaceutical company, Praxis..

Geron Corporation (GERN) Investor Outlook: Analyzing a Potential 248% Upside in the Biotechnology Sector

Investors eyeing the healthcare sector may find an intriguing opportunity in Geron Corporation (NASDAQ: GERN), a biopharmaceutical company making strides in oncology therapeutics. With a market capitalization of approximately $783.82..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Exploring a Potential 354% Upside

Niagen Bioscience, Inc. (NAGE), a player in the Consumer Defensive sector, specifically within the Packaged Foods industry, is capturing investor attention with a staggering potential upside of 354.26%. As the..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Growth with a 1.98% Potential Upside

AMN Healthcare Services Inc (AMN) stands as a prominent player in the healthcare sector, specifically within the medical care facilities industry. Based in Dallas, Texas, and founded in 1985, AMN..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A 176% Upside Potential Beckons Investors

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a dynamic player in the healthcare sector, presents a compelling opportunity within the biotechnology industry. With a market capitalization of $716.79 million and a focus..

Atrium Therapeutics, Inc. (RNA): Stock Analysis Reveals 218.88% Potential Upside

Atrium Therapeutics, Inc. (RNA) has garnered significant attention from investors, thanks to its robust potential upside of 218.88%. As a key player in the biotechnology sector, the company is pioneering..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: An Insight into Its 49% Potential Upside

Investors in the biotechnology sector often look for companies with innovative solutions to complex medical challenges, and Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a compelling player in this arena. With..

Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 150% Upside in the Biotech Sector

Legend Biotech Corporation (NASDAQ: LEGN) is capturing investor attention with its significant growth potential in the biotechnology sector, thanks to an impressive 150.40% potential upside. With a market capitalization of..

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring Potential Upside Amidst a Challenging Landscape

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneering force in the biotechnology sector, is drawing attention from investors with its innovative approach to genetic therapies. With a market cap of $1.85..

Integer Holdings Corporation (ITGR) Stock Analysis: Navigating a Complex Market with a 0.00% Dividend Yield

Integer Holdings Corporation (NYSE: ITGR) stands as a prominent player in the healthcare sector, particularly within the medical devices industry. Headquartered in Plano, Texas, this U.S.-based company is a crucial..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds